Explore NVAX stock price, latest earnings, technical analysis, analyst ratings, and forecast. Is NVAX stock a buy? Get balanced insights for investors as of February 2026.
Introduction
Novavax develops vaccines using protein-based tech. It gained fame for its COVID-19 shot. Investors watch NVAX stock now due to recent profit turn and high short interest. Broader market volatility from biotech shifts and economic slowdowns impacts it.
Latest Stock Price & Trend
NVAX stock closed at $6.57 on recent trading. It saw a small gain of 0.8% from the day’s low. Over five days, it held steady amid volume of 4.2 million shares. The one-month trend shows mild recovery after dips.
In three months, NVAX stock rose about 40% from lows. Six-month performance hit new highs four times, up sharply. Year-to-date, it climbed 28.55% with one peak. The 52-week range spans $5.01 low to $10.64 high.
Overall trend leans bullish short-term but sideways yearly. This signals rebound potential for investors yet caution on peaks.
Technical Analysis
Support levels sit near $6.52, the recent low where buyers stepped in. Resistance looms at $6.72, capping upside. RSI at 62.7 shows neutral momentum, not overbought.
MACD at 0.664 gives a buy signal for short-term trades. The 50-day moving average trends above price, hinting pullback risk. No golden cross yet; 200-day average lags.
Volume stays high at millions daily, supporting moves. These indicators matter as they spot entry points and reversals for beginners.
Analyst Ratings & Price Targets
Analysts split with recent sells like Citigroup’s $6 target. HC Wainwright holds buy at $19. Average target around $118 from some, but varied.
JP Morgan keeps underweight at $7. Upgrades rare lately; downgrades noted. Wall Street sees mixed views on vaccine sales. Sentiment suggests caution for NVAX stock.
Insider Activity
Insiders sold more than bought last year, net sales of shares worth $117k vs buys of $63k. No major recent buys signal confidence.
Selling trend continues over two years, per reports. This may imply caution from management on NVAX stock outlook.
Valuation Analysis
Trailing P/E stands at 3.1, low for biotech. Price-to-sales at 1.22 shows cheap sales multiple. Revenue grew YoY to $1.12 billion from $682 million.
EPS flipped to profit with $0.11 last quarter vs expected loss. Free cash flow negative; cash at $751 million, debt managed. Compared to peers, NVAX stock appears undervalued on growth.
Recent Earnings & Catalysts
Q4 2025 EPS beat at $0.11 vs -$0.56 expected. Full-year revenue hit $1.12 billion, up 65%. Net income $440 million vs prior loss.
Guidance focuses on expense cuts, met R&D goals. Catalysts include combo vaccine deals. Earnings boosted NVAX stock post-report.
Bullish Case
Strong revenue growth from vaccines drives upside. Protein platform offers edge over mRNA rivals. Cash buffer supports R&D. Expense controls improve margins.
Bearish Case
High competition from Pfizer, Moderna slows sales. Short interest at 36.5% of float risks squeezes but adds pressure. Regulatory hurdles loom. Economic slowdown hits healthcare spend.
Market Sentiment
Short interest high at 36.51%, days to cover 19.78. Institutional ownership 58%. Retail shows accumulation vs shorts. Sentiment mixes optimistic on earnings, fearful on debt.
Short-Term Outlook
Technicals show buy signals with neutral RSI. Volume supports momentum. Expect volatility next weeks from shorts.
Medium to Long-Term Outlook
Solid cash aids pipeline. Industry grows on new viruses. Competitive moat in tech, but sales risks persist. Long-term investors should watch NVAX stock.
FAQ
Is NVAX stock a buy right now? Mixed ratings; undervalued but risky. Weigh earnings beat.
What is the NVAX stock price target? Averages vary, $6-$19 recent.
NVAX forecast? Bullish on growth, bearish on competition.
Major risks for NVAX stock? High shorts, rivals.
Suggestions
- Compare with Opendoor stock analysis
- See our biotech sector forecast
- Read vaccine stock valuation guide
Final Balanced Conclusion
Hold NVAX stock. Earnings progress offsets risks like shorts and competition. Watch catalysts closely.
Disclaimer: This article is for informational purposes only and not financial advice.